4-(4-Methoxybenzyl)piperidine hydrochloride

Catalog No. :
ACLKES701
CAS No. :
37581-27-4
Molecular Formula :
C13H20ClNO
Molecular Weight :
241.76

IUPAC Name:4-(4-methoxybenzyl)piperidine hydrochloride

4-(4-Methoxybenzyl)piperidine hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g95%$59.00Login to see priceIn stockInquiry
25g95%$252.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(4-Methoxybenzyl)piperidine hydrochloride
IUPAC Name4-(4-methoxybenzyl)piperidine hydrochloride
MDL No.MFCD03840137
Molecular FormulaC13H20ClNO
Molecular Weight241.76
SMILESCOC1=CC=C(C=C1)CC2CCNCC2.[H]Cl
InChI KeyZYMIUGACXVWBTE-UHFFFAOYSA-N
Synonym4-(4-METHOXYBENZYL)PIPERIDINE HYDROCHLORIDE;4-[(Piperidin-4-yl)methyl]anisole hydrochloride;4-[(4-methoxyphenyl)methyl]piperidine hydrochloride;4-(4-METHOXYBENZYL)PIPERIDINE HCL;4-[(4-methoxyphenyl)methyl]piperidine;Piperidine, 4-[(4-methoxyphenyl)methyl]-, hydrochloride;Piperidine,4-[(4-methoxyphenyl)methyl]-,hydrochloride(1:1);7-Benzofuranbutanoicacid,α,γ-dioxo-,ethylester
CAS No.37581-27-4
PubChem CID17039488

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312+P330-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACLKES701 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLKES701 route product structure diagram
    ACLKES70137581-27-4 In Stock
Inquiry

2. ACLKES701 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLKES701 route product structure diagram
    ACLKES70137581-27-4 In Stock
Inquiry

Comments (0)